Curcumin. Novel Turmeric Compound Delivers Much More Curcumin to the Blood part 1

10925 Views
Was this article interesting to you?

Scientific Sources

BCM-95 bioavailability?

BCM-95 delivers up to 7 times more pharmacologically bioactive curcumin to blood than commercial products. 400mg BCM-95 = 2,772mg standard "95%" extract or 2,548mg plant-bound with piperine. Life Extension trial: 6.93 times more curcumin.

Why bioavailability matters?

Standard curcumin has poor absorption into bloodstream, limiting effectiveness despite vast health benefits. Requires high doses to achieve desired blood levels.

What was Life Extension study?

Documented pharmacokinetics (absorption, circulation, metabolism) in human subjects. Compared BCM-95 with plant-bound curcumin+piperine and standard 95% extract. Verified significantly greater concentrations for sustained time.

Curcumin health benefits?

Prevents/fights cancer, cardiovascular disease, Alzheimer's, multiple sclerosis, cystic fibrosis, cataracts, diabetes complications. Anti-inflammatory via NF-κB inhibition. Antibacterial, antifungal, antiviral, antioxidant capabilities.

Rat study findings?

BCM-95 bioavailability 7.8 times higher than conventional curcumin in rats, confirming enhanced absorption across species.

  • BCM-95 delivers 6-7 times more curcumin to blood than standard products
  • 400mg BCM-95 = 2,772mg standard extract or 2,548mg plant-bound with piperine
  • Life Extension trial: 6.93 times more curcumin to bloodstream
  • Rat studies: 7.8 times higher bioavailability than conventional curcumin
  • Rapidly absorbed from digestive system allowing more disease-fighting chemicals to circulate
  • Sustained curcumin levels for longer time period in circulation
  • Inhibits NF-κB activation potent inducer of chronic inflammation
  • Fights cancer, cardiovascular disease, Alzheimer's, MS, cystic fibrosis
  • Antibacterial, antifungal, antiviral capabilities
  • Protects against cataracts, diabetes damage, psoriasis

BCM-95 Enhanced Curcumin Protocol

Step 1: Baseline

Assess inflammatory markers, oxidative stress, conditions requiring curcumin. Previous curcumin response if any.

Step 2: BCM-95 Dosing

400mg BCM-95 provides equivalent of 2,772mg standard curcumin due to 6-7x enhanced bioavailability. Rapidly absorbed, sustained blood levels.

Step 3: Multi-Condition Benefits

Targets inflammation via NF-κB inhibition. Anti-cancer, cardiovascular protection, Alzheimer's prevention, MS treatment potential. Antibacterial, antifungal, antiviral.

Step 4: Therapeutic Monitoring

Track response. Enhanced bioavailability means therapeutic effects at lower doses than standard curcumin requiring 2,772mg to match 400mg BCM-95.

  • Inflammatory conditions (ICD-10: M79.3)
  • Cancer prevention (Z80.9)
  • Cardiovascular disease (I25.10)
  • Alzheimer's risk (G30.9)
  • Multiple sclerosis (G35)
  • Cystic fibrosis (E84.9)
  • Diabetes complications (E11.9)
  • Poor curcumin absorption (K90.9)
  • Hypersensitivity to curcumin/turmeric
  • Bile duct obstruction (stimulates bile)
  • Bleeding disorders (antiplatelet effects)
  • Surgery within 2 weeks
  • Pregnancy/breastfeeding

Life Extension Bioavailability Study: Compared BCM-95 with plant-bound curcumin+piperine and standard 95% extract. Documented pharmacokinetics—absorption, circulation, metabolism in human subjects. BCM-95 rapidly absorbed from digestive system. Trial showed 6.93 times more curcumin to bloodstream than standard formulations.

Dose Equivalence: One 400mg dose BCM-95 bioavailability-enhanced extract equivalent to 2,772mg standard "95%" curcumin extract or 2,548mg plant-bound curcumin with piperine. BCM-95 is six to seven times more bioavailable than ordinary 95% extract.

Animal Confirmation: Rat studies showed BCM-95 bioavailability 7.8 times higher than conventional curcumin, confirming enhanced absorption across species.

Citation: Antony B, Benny M, Kaimal TNB, et al. Controlled randomized comparative human oral bioavailability of Biocurcumax (BCM-95 CG)—novel bioenhanced preparation of curcuminoids. Study submitted for publication, 2007.